[Treatment of patients with stage III non-small cell lung cancer: concurrent high-dose chemotherapy and radiotherapy]

Autor: Sy, El Sharouni, Jg, Aerts, Senan S, Dk, Ruysscher, Hj, Groen, Ma, Paul, Egbert Smit, Ej, Vonk, Af, Verhagen, Fm, Schramel

Publikováno v: Europe PubMed Central

The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting ofchemotherapy and radi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::9cd71321e0a93d82c82c7e8de8e65b48
http://europepmc.org/abstract/med/19192584

Improving survival prediction of oesophageal cancer patients treated with external beam radiotherapy for dysphagia.

Autor: Jeene PM; Amsterdam UMC location University of Amsterdam, Radiotherapy, Amsterdam, the Netherlands.; Radiotherapiegroep, Deventer, The Netherlands., Kuijper SC; Amsterdam UMC location University of Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Medical Oncology, Amsterdam, the Netherlands., van den Boorn HG; Amsterdam UMC location University of Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Medical Oncology, Amsterdam, the Netherlands., El Sharouni SY; Department of Radiotherapy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Braam PM; Department of Radiotherapy, Radboud University Medical Center, Radboud University, Nijmegen, The Netherlands., Oppedijk V; Radiotherapeutisch Instituut Friesland, Leeuwarden, The Netherlands., Verhoeven RHA; Amsterdam UMC location University of Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Medical Oncology, Amsterdam, the Netherlands.; Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands., Hulshof MCCM; Amsterdam UMC location University of Amsterdam, Radiotherapy, Amsterdam, the Netherlands., van Laarhoven HWM; Amsterdam UMC location University of Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Medical Oncology, Amsterdam, the Netherlands.

Publikováno v: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2022 Jul; Vol. 61 (7), pp. 849-855. Date of Electronic Publication: 2022 Jun 01.

Patient-reported outcomes after external beam radiotherapy versus brachytherapy for palliation of dysphagia in esophageal cancer: A matched comparison of two prospective trials.

Autor: van Rossum PSN; Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. Electronic address: P.S.N.vanRossum-2@umcutrecht.nl., Jeene PM; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands; Radiotherapiegroep, location Deventer, The Netherlands. Electronic address: P.Jeene@radiotherapiegroep.nl., Rozema T; Instituut Verbeeten, Tilburg, The Netherlands., Braam PM; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Lips IM; Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands., Muller K; Radiotherapiegroep, location Deventer, The Netherlands., van Kampen D; Zuidwest Radiotherapeutisch Instituut, Vlissingen and Roosendaal, The Netherlands., Vermeulen BD; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands., Homs MYV; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Oppedijk V; Radiotherapeutisch Instituut Friesland, Leeuwarden, The Netherlands., Berbée M; Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands., Hulshof MCCM; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Siersema PD; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands., El Sharouni SY; Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands.

Publikováno v: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2021 Feb; Vol. 155, pp. 73-79. Date of Electronic Publication: 2020 Oct 14.

Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study.

Autor: Witlox WJA; Maastricht University Medical Centre(+), Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands. Electronic address: willem.witlox@mumc.nl., Ramaekers BLT; Maastricht University Medical Centre(+), Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands., Joore MA; Maastricht University Medical Centre(+), Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands; Care and Public Health Research Institute (CAPHRI), Maastricht University, The Netherlands., Dingemans AC; Maastricht University Medical Center(+), Department of Pulmonology, GROW Research Institute, The Netherlands., Praag J; Erasmus University Medical Center, Department of Radiation Oncology, Rotterdam, The Netherlands., Belderbos J; Netherlands Cancer Institute (NKI), Department of Radiation Oncology, Amsterdam, The Netherlands., Tissing-Tan C; Radiotherapy Institute Arnhem, Arnhem, The Netherlands., Herder G; Antonius Hospital Nieuwegein, Department of Pulmonology, The Netherlands., Haitjema T; Medical Center Alkmaar, Department of Pulmonology, The Netherlands., Ubbels JF; University of Groningen, University Medical Center Groningen, Department of Radiation Oncology, The Netherlands., Lagerwaard J; Free University Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands., El Sharouni SY; University Medical Center Utrecht, Department of Radiation Oncology, The Netherlands., Stigt JA; Isala Hospital, Department of Pulmonology, Zwolle, The Netherlands., Smit EF; Netherlands Cancer Institute (NKI), Department of Pulmonology, Amsterdam, The Netherlands., van Tinteren H; Netherlands Cancer Institute (NKI), Department of Biometrics, Amsterdam, The Netherlands., van der Noort V; Netherlands Cancer Institute (NKI), Department of Biometrics, Amsterdam, The Netherlands., Groen HJM; University of Groningen and University Medical Center Groningen, Department of Pulmonary Diseases, The Netherlands., De Ruysscher DKM; Maastricht University Medical Centre(+), Department of Radiation Oncology (Maastro Clinic), GROW School of Oncology and Developmental Biology, The Netherlands; KU Leuven, Radiation Oncology, Belgium.

Publikováno v: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2020 Mar; Vol. 144, pp. 65-71. Date of Electronic Publication: 2019 Nov 14.

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.

Autor: De Ruysscher D; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Dingemans AC; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Praag J; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Belderbos J; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Tissing-Tan C; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Herder J; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Haitjema T; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Ubbels F; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Lagerwaard F; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., El Sharouni SY; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Stigt JA; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Smit E; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., van Tinteren H; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., van der Noort V; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium., Groen HJM; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaard, Free University Medical Center, Amsterdam; Caroline Tissing-Tan, Radiotherapy Institute Arnhem, Arnhem; Judith Herder, Antonius Hospital Nieuwegein, Nieuwegein; Tjeerd Haitjema, Medical Center Alkmaar, Alkmaar; Fred Ubbels and Harry J.M. Groen, University of Groningen; University Medical Center Groningen, Groningen; Sherif Y. El Sharouni, University Medical Center Utrecht, Utrecht; Jos A. Stigt, Isala Hospital, Zwolle, The Netherlands; and Dirk De Ruysscher, KU Leuven, Leuven, Belgium.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Aug 10; Vol. 36 (23), pp. 2366-2377. Date of Electronic Publication: 2018 May 22.